TIDMCOG
RNS Number : 7330X
Cambridge Cognition Holdings PLC
24 February 2017
24 February 2017
Cambridge Cognition Holdings Plc
('Cambridge Cognition')
Takeda and Cognition Kit partner in study to pilot wearable
software in patients with Major Depressive Disorder (MDD)
Cambridge, England, and Deerfield, IL, February 24 2017 - Takeda
Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda
Pharmaceutical Company Limited (TSE:4502) and Cognition Kit Limited
('Cognition Kit' or the 'Company'), a joint venture between
Cambridge Cognition and Ctrl Group Limited, announced a
collaboration to pilot the use of a specially designed app on an
Apple Watch wearable to monitor and assess cognitive function in
patients with Major Depressive Disorder (MDD).
Depression (MDD) is the leading cause of disability worldwide,
affecting an estimated 350 million people of all ages.(1) Cognitive
problems are common in major depression and may be under recognized
by both patients and clinicians.(2,3) Cognitive testing provides
the opportunity to detect and understand the pattern of cognitive
symptoms in patients with MDD. The Cognition Kit app is designed as
a step forward in assessing those symptoms, advancing patient
assessment and monitoring outside of the lab and into everyday life
to help maximize patient engagement and potential treatment.
The study will involve 30 participants, aged 18-65 with a
clinical diagnosis of mild to moderate depression who have been
prescribed an antidepressant for Major Depressive Disorder. The
present study aims to evaluate feasibility, compliance and to
understand how measures of mood and cognition on wearable
technology compare to more traditional neuropsychological testing
and patient reported assessments. The output of the study is
expected in the first half of 2017.
The collaboration is part of a shared commitment between Takeda
and Cognition Kit to improve mental health worldwide through
leading research and innovation.
"By combining wearable technology with world leading
neuroscience, we've created an app that collects real time passive
and active high-frequency mental health data," said Jenny Barnett,
PhD, Cognition Kit. "Being able to access data regularly from daily
life can help clinical decision making. Healthcare professionals
can obtain patient data and increase patient engagement in their
treatment."
"Takeda is committed to CNS and the mental health community,"
said Nicole Mowad-Nassar, Vice President, External Partnerships, at
Takeda Pharmaceuticals U.S.A. "This collaboration is part of our
strategy to embrace new technology to better understand the patient
experience and assist healthcare professionals in creating improved
patient care pathways."
This collaboration is the first contract signed by Cognition Kit
Limited, the joint venture of Cambridge Cognition and London based
Ctrl Group, since launching the wearable cognitive technology in
2016, with significant interest already gained from a number of
commercial partners.
For information about wearable cognitive assessment technology
from Cognition Kit visit: www.cognitionkit.com
(1) World Health Organization.
http://www.who.int/mediacentre/factsheets/fs369/en/ [last accessed
13 June 2015]
(2) Conradi HJ, Ormel J, de Jonge P. Presence of individual
(residual) symptoms during depressive episodes and periods of
remission: a 3-year prospective study. Psychol Med
2011;41(6):1165-74.
(3) Enabling Discovery, Development, and Translation of
Treatments for Cognitive Dysfunction in Depression: Workshop
Summary. Editors Forum on Neuroscience and Nervous System
Disorders; Board on Health Sciences Policy; Institute of Medicine;
The National Academies of Sciences, Engineering, and Medicine.
Washington (DC): National Academies Press (US); 2015 Oct.
Notes to editors
About Cognition Kit Limited
Cognition Kit is a joint venture between Cambridge Cognition and
Ctrl Group formed in 2016 to develop digital health tools on mobile
and wearable devices. Cognition Kit software takes research out of
the lab and into daily life, enabling doctors, scientists and the
public to better understand and manage day-to-day brain health.
www.cognitionkit.com @CognitionKit hello@cognitionkit.com
About Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceutical Company Limited is a global,
R&D-driven pharmaceutical company committed to bringing better
health and a brighter future to patients by translating science
into life-changing medicines. Takeda focuses its research efforts
on oncology, gastroenterology and central nervous system
therapeutic areas. It also has specific development programs in
specialty cardiovascular diseases as well as late-stage candidates
for vaccines. Takeda conducts R&D both internally and with
partners to stay at the leading edge of innovation. New innovative
products, especially in oncology and gastroenterology, as well as
its presence in emerging markets, fuel the growth of Takeda. More
than 30,000 Takeda employees are committed to improving quality of
life for patients, working with our partners in health care in more
than 70 countries. For more information, visit
http://www.takeda.com/news.
Takeda Pharmaceuticals U.S.A., Inc. is located in Deerfield,
Ill., and is the U.S. commercial organization of Takeda
Pharmaceutical Company Limited.
Additional information about Takeda is available through its
corporate website, www.takeda.com, and additional information about
Takeda Pharmaceuticals U.S.A., Inc. is available through its
website, www.takeda.us.
About Cambridge Cognition Holdings PLC
Cambridge Cognition is a neuroscience digital health company
specialising in the precise measurement of clinical outcomes in
neurological disorders. The Company develops and markets validated
near patient assessment products using cognition as a biomarker to
improve understanding, diagnosis and treatment in brain health
worldwide.
Partners include the world's leading drug development companies,
academic institutions and public-private health organisations.
www.cambridgecognition.com @CANTABconnect press@camcog.com
About Ctrl Group Limited
Ctrl Group believe that new technologies have the potential to
transform healthcare and medical research by increasing efficiency
and creating more personalised medicine. We are a team of
designers, researchers, software developers and healthcare experts
who work internationally with healthcare companies and providers
who want to use new technology to improve people's health.
www.ctrl-group.com @Ctrl_Group hello@ctrl-group.com
Enquiries
Takeda Pharmaceuticals U.S.A. Tel: +1-224-554-1474
Corporate Communications Roseanne.Durril@takeda.com
Roseanne Durril
Cambridge Cognition Holdings PLC Tel: 01223 810
Steven Powell, Chief Executive 700
Officer press@camcog.com
Noah Konig, Director of Product
Marketing and Communications
Ctrl Group Limited Tel: 0207 490
Ben Fehnert, Director 2449
James King, Director hello@ctrl-group.com
finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220
Geoff Nash / Simon Hicks 0500
Alice Lane (Corporate Finance)
(Corporate Broking)
Dowgate Capital Stockbrokers Limited Tel: 01293 517
David Poutney / James Serjeant 744
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBRGDDLXDBGRX
(END) Dow Jones Newswires
February 24, 2017 02:00 ET (07:00 GMT)